The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Nifedipine: Dose-Related Increase in Mortality in Patients With Coronary Heart Disease
Abstract
Background The purpose of this study was to assess the effect of the dose of nifedipine, a dihydropyridine calcium antagonist, on the increased risk of mortality seen in the randomized secondary-prevention trials and to review the mechanisms by which this adverse effect might occur. Methods and Results We restricted the dose-response meta-analysis to the 16 randomized secondary-prevention trials of nifedipine for which mortality data were available. Recent trials of any calcium antagonist and formulation were also reviewed for information about the possible mechanisms of action that might increase mortality. Overall, the use of nifedipine was associated with a significant adverse effect on total mortality (risk ratio, 1.16, with a 95% CI of 1.01 to 1.33). This summary estimate fails to draw attention to an important dose-response relationship. For daily doses of 30 to 50, 60, and 80 mg, the risk ratios for total mortality were 1.06 (95% CI, 0.89 to 1.27), 1.18 (95% CI, 0.93 to 1.50), and 2.83 (95% CI, 1.35 to 5.93), respectively. In a formal test of dose response, the high doses of nifedipine were significantly associated with increased mortality ( P =.01). While the mechanism of this adverse effect is not known, there are several plausible explanations, including the established proischemic effect, negative inotropic effects, marked hypotension, recently reported prohemorrhagic effects attributed to antiplatelet and vasodilatory actions of calcium antagonists, and possibly proarrhythmic effects. Conclusions In patients with coronary disease, the use of short-acting nifedipine in moderate to high doses causes an increase in total mortality. Other calcium antagonists may have similar adverse effects, in particular those of the dihydropyridine type. Long-term safety data are lacking for most calcium antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210629 · Cited by 3,300
QUANTITATIVE METHODS IN THE REVIEW OF EPIDEMIOLOGIC LITERATURE1
GREENLAND, S. (1987) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036298 · Cited by 1,644
Circadian variation and triggers of onset of acute cardiovascular disease.
Muller, J. E., Tofler, G. H., & Stone, P. H. (1989) · Circulation · doi:10.1161/01.cir.79.4.733 · Cited by 1,426
The Effect of Diltiazem on Mortality and Reinfarction after Myocardial Infarction
The Multicenter Diltiazem Postinfarction Trial Research Group* (1988) · New England Journal of Medicine · doi:10.1056/nejm198808183190701 · Cited by 825
Retardation of angiographic progression of coronary artery disease by nifedipine
Lichtlen, P. R., Rafflenbeul, W., Hecker, H., Jost, S., Hugenholtz, P. G., & Deckers, J. W. (1990) · The Lancet · doi:10.1016/0140-6736(90)91121-p · Cited by 611
Teo, K. K. (1993) · JAMA · doi:10.1001/jama.270.13.1589 · Cited by 608
Meta-analysis of Epidemiologic Dose-Response Data
Berlin, J. A., Longnecker, M. P., & Greenland, S. (1993) · Epidemiology · doi:10.1097/00001648-199305000-00005 · Cited by 571
Goldstein, R. E., Boccuzzi, S. J., Cruess, D., & Nattel, S. (1991) · Circulation · doi:10.1161/01.cir.83.1.52 · Cited by 521
Calcium channel blockers in acute myocardial infarction and unstable angina: an overview.
Held, P. H., Yusuf, S., & Furberg, C. D. (1989) · BMJ · doi:10.1136/bmj.299.6709.1187 · Cited by 426
Self-citationElkayam, U., Amin, J., Mehra, A., Vasquez, J., Weber, L., & Rahimtoola, S. H. (1990) · Circulation · doi:10.1161/01.cir.82.6.1954 · Cited by 343
Gore, J. M., Sloan, M., Price, T. R., Randall, A. M., Bovill, E., Collen, D., Forman, S., Knatterud, G. L., Sopko, G., & Terrin, M. L. (1991) · Circulation · doi:10.1161/01.cir.83.2.448 · Cited by 315
(1991) · New England Journal of Medicine · doi:10.1056/nejm199105023241801 · Cited by 287
Yusuf, S., Held, P., & Furberg, C. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90944-g · Cited by 284
Self-citation(1986) · Heart · doi:10.1136/hrt.56.5.400 · Cited by 271
Muller, J. E., Morrison, J., Stone, P. H., Rude, R. E., Rosner, B., Roberts, R., Pearle, D. L., Turi, Z. G., Schneider, J. F., & Serfas, D. H. (1984) · Circulation · doi:10.1161/01.cir.69.4.740 · Cited by 264
Nifedipine in Unstable Angina: A Double-Blind, Randomized Trial
Gerstenblith, G., Ouyang, P., Achuff, S. C., Bulkley, B. H., Becker, L. C., Mellits, E. D., Baughman, K. L., Weiss, J. L., Flaherty, J. T., Kallman, C. H., et al. (1982) · New England Journal of Medicine · doi:10.1056/nejm198204153061501 · Cited by 236
Goldbourt, U., Behar, S., Reicher-Reiss, H., Zion, M., Mandelzweig, L., & Kaplinsky, E. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.153.3.345 · Cited by 173
Roine, R. O. (1990) · JAMA · doi:10.1001/jama.1990.03450240073043 · Cited by 173
Secondary prevention reinfarction Israeli nifedipine trial (SPRINT).
THE ISRAELI SPRINT STUDY GROUP (1988) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a062511 · Cited by 156
Production of ischaemic cardiac pain by nifedipine.
Jariwalla, A. G., & Anderson, E. G. (1978) · BMJ · doi:10.1136/bmj.1.6121.1181 · Cited by 131
ANTIHYPERTENSIVE TREATMENT, MYOCARDIAL INFARCTION, AND NOCTURNAL MYOCARDIAL ISCHAEMIA
Floras, J. S. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90745-3 · Cited by 118
Thadani, U., Zellner, S. R., Glasser, S. P., Bittar, N., Montoro, R. J., Miller, A. B., CHAITMAN, B. R., Schulman, P. M., Stahl, A., & DiBianco, R. (1991) · Circulation · doi:10.1161/01.cir.84.6.2398 · Cited by 58
Egstrup, K., & Andersen, P. E. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90735-u · Cited by 47
(1991) · The Lancet · doi:10.1016/0140-6736(91)90208-7 · Cited by 33
Scheidt, S. S., LeWinter, M. M., Hermanovich, J., Venkataraman, K., & Freedman, D. D. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90343-7 · Cited by 30
Calcium antagonists in the treatment of ischemic heart disease
Held, P. H., & Yusuf, S. (1994) · Coronary Artery Disease · doi:10.1097/00019501-199401000-00004 · Cited by 26
Cited by
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
WRITING COMMITTEE MEMBERS*, O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,725
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989
Metadata
- Authors
- Furberg, C. D., Psaty, B. M., & Meyer, J. V.
- Venue
- Circulation
- Published
- 1995-09
- Volume
- 92
- Issue
- 5
- Pages
- 1326-1331
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2092805838
- Cited by
- 1,173
- References
- 26
- FWCI
- 103.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.